[Federal Register Volume 84, Number 220 (Thursday, November 14, 2019)]
[Notices]
[Pages 61917-61919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24689]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Findings of research misconduct have been made against Dr. 
Sudhakar Yakkanti (Respondent) (formerly named Sudhakar Akulapalli),\1\ 
former staff scientist and Director of the Cell Signaling, Retinal & 
Tumor Angiogenesis Laboratory, Boys Town National Research Hospital 
(BTNRH). Respondent engaged in research misconduct in research 
supported by U.S. Public Health Service (PHS) funds, specifically, 
National Cancer Institute (NCI), National Institutes of Health (NIH), 
grant R01 CA143128, National Eye Institute (NEI), NIH, grants R01 
EY018179 and R01 EY16695, and National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK), NIH, grants R01 DK055000, R01 
DK055001, R01 DK062987, and R01 DK051711. The administrative actions, 
including debarment for a period of five (5) years, were implemented 
beginning on August 24, 2019, and are detailed below.
---------------------------------------------------------------------------

    \1\ The Respondent changed his name from Sudhakar Akulapalli to 
Sudhakar Yakkanti during the BTNRH inquiry.

FOR FURTHER INFORMATION CONTACT: Elisabeth A. Handley, Interim 
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 
---------------------------------------------------------------------------
240, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of 
Research Integrity (ORI) has taken final action in the following case:
    Dr. Sudhakar Yakkanti, Boys Town National Research Hospital: Based 
upon the evidence and findings of an investigation report by BTNRH and 
additional information obtained by ORI during its oversight review of 
the BTNRH investigation, ORI found that Dr. Sudhakar Yakkanti, former 
staff scientist and Director of the Cell Signaling, Retinal & Tumor 
Angiogenesis Laboratory, BTNRH, engaged in research misconduct in 
research supported by PHS funds, specifically, NCI, NIH, grant R01 
CA143128, NEI, NIH, grants R01 EY018179 and R01 EY16695, and NIDDK, 
NIH, grants R01 DK055000, R01 DK055001, R01 DK062987, and R01 DK051711.
    ORI found by a preponderance of the evidence that Respondent 
intentionally, knowingly, or recklessly falsified and/or fabricated 
figures in the following eight (8) unfunded NIH grant applications, one 
(1) funded NIH grant application, seven (7) publications, and two (2) 
unpublished manuscripts:

 R01 CA115763-01A2 submitted to NCI, NIH (unfunded)
 R21 CA155796-01 submitted to NCI, NIH (unfunded)
 R01 CA166195-01 submitted to NCI, NIH (unfunded)
 R01 CA143128-01 submitted to NCI, NIH (unfunded)
 R01 CA143128-04 submitted to NCI, NIH (unfunded)
 R01 EY020539-01 submitted to NEI, NIH (unfunded)
 R01 EY020539-01A1 submitted to NEI, NIH (unfunded)
 R01 EY024967-01 submitted to NEI, NIH (unfunded)
 R01 CA143128-01A1 submitted to NCI, NIH (funded)
 Biochemistry 2000;39(42):12929-12938 (hereafter referred to as 
``Biochem 2000'')
 Proc. Natl. Acad. Sci. U.S.A. 2003;100(8):4766-4771 (hereafter 
referred to as ``PNAS 2003'')
 The Journal of Clinical Investigation 2005;115(10):2801-2810 
(hereafter referred to as ``JCI 2005'')
 Invest. Ophthalmol. Vis. Sci. 2009;50(10):4567-4575 (hereafter 
referred to as ``IOVS 2009'')
 Pharmaceutical Research 2008;25(12):2731-2739 (hereafter 
referred to as ``Pharm Research 2008'')
 Scientific Reports 2014;4(4136):1-9 (hereafter referred to as 
``Sci Reports 2014'')
 Current Eye Res. 2010 Jan;35(1):44-55 (hereafter referred to 
as ``CER 2010'')
 Tumstatin inhibits Choroidal Neovascularization by Inhibiting 
MMP-2 activation in-vitro and in vivo. Submitted to Molecular Vision on 
February 7, 2011 (hereafter referred to as ``Mol Vis Sub 2011'') 
(unpublished)
 Inhibitory Effect of Tumstatin on Corneal Neovascularization 
Both In-vitro and In-vivo. Submitted to Journal of Clinical & 
Experimental Ophthalmology on January 16, 2011 (hereafter referred to 
as ``JCEO Sub 2011'') (unpublished)

    Specifically, ORI found by a preponderance of the evidence that

[[Page 61918]]

Respondent engaged in research misconduct by intentionally, knowingly, 
or recklessly:

 Falsifying an image from an in vivo choroidal 
neovascularization (CNV) experiment by falsely relabeling an image 
representing results from an experiment with the anti-angiogenic 
molecule arresten ([alpha]1NC1) to represent results from a different 
CNV experiment with a different anti-angiogenic molecule, hexastatin 
([alpha]6NC1) in Figure 9A (right panel) of grant application R01 
CA166195-01
 falsifying an image from an in vivo CNV experiment by falsely 
relabeling an image representing results from an experiment with the 
anti-angiogenic molecule hexastatin ([alpha]6NC1) to represent results 
from different CNV experiments with different anti-angiogenic 
molecules:

    --Arresten ([alpha]1NC1) in Figure 10A (right panel) of grant 
application R01 EY020539-01A1
    --tumstatin ([alpha]3NC1) in Figure 6A (right panel) of Mol Vis Sub 
2011
 falsifying and/or fabricating bar graphs in Figure 9B of grant 
application R01 CA166195-01, which was based on the falsified image in 
Figure 9A (right panel) of grant application R01 CA166195-01
 falsifying and/or fabricating bar graphs in Figure 6B of Mol 
Vis Sub 2011, which was based on the falsified image in Figure 6A 
(right panel) of Mol Vis Sub 2011
 falsifying and/or fabricating bar graphs in Figure 10B of 
grant application R01 EY020539-01A1, which was based on the falsified 
image in Figure 10A of grant application R01 EY020539-01A1
 falsifying microscope images of endothelial tube formation 
assays by labeling one image as two different experiments:

    --A control in an experiment performed in Human umbilical vein 
endothelial cells (HUVECs) in Figure 1D (first panel) of grant 
application R21 CA155796-01
    --a control in an experiment performed in mouse choroidal 
endothelial cells (MCECs) in Figure 2B (first panel) of grant 
application R01 EY020539-01A1
 falsifying microscope images of endothelial tube formation 
assays by reusing and falsely labeling one image as three different 
experiments:

    --HUVECs treated with 0.5 [micro]M hexastatin ([alpha]6(IV)NC1) in 
Figure 1D (third panel) of grant application R21 CA155796-01
    --MCECs treated with 0.5 [micro]M arresten ([alpha]1(IV)NC1) in 
Figure 2B (second panel) of grant application R01 EY020539-01A1
    --MCECs treated with 1.0 [micro]M tumstatin ([alpha]3(IV)NC1) in 
Figure 2C (bottom right panel) of Mol Vis Sub 2011
 falsifying Western blot images by reusing and falsely labeling 
one image as four different experiments:

    --The protein band FAK from HUVECs treated with hexastatin 
([alpha]6(IV)NC1) in Figure 3A (bottom panel) of grant application R21 
CA155796-01 and Figure 4A (bottom panel) of grant application R01 
CA166195-01
    --the protein band FAK from MCECs treated with arresten 
([alpha]1(IV)NC1) in Figure 5A (bottom panel) of grant application R01 
EY020539-01A1
    --the protein band Raf from HUVECs treated with rh-Endo in Figure 
5A (bottom panel) of PNAS 2003
    --the protein band FAK from mouse retinal pigmented epithelial cell 
(MRPECs) treated with arresten ([alpha]1(IV)NC1) in Figure 5B (bottom 
panel) of grant application R01 EY020539-01 and in Figure 7B (bottom 
panel) of IOVS 2009
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --HUVECs treated with rh-Endo in Figure 5D (middle panel) of PNAS 
2003
    --mouse retinal endothelial cells (MRECs) treated with arresten 
([alpha]1(IV)NC1) in Figure 7C (top panel) of IOVS 2009
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --HUVECs treated with hexastatin ([alpha]6(IV)NC1) in Figure 3C 
(top panel) of grant application R21 CA155796-01
    --MCECs treated with arresten ([alpha]1(IV)NC1) in Figure 5B (top 
panel) of grant application R01 EY020539-01A1
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --HUVECs treated with hexastatin ([alpha]6(IV)NC1) in Figure 3C 
(bottom panel) of grant application R21 CA155796-01
    --MCECs treated with arresten ([alpha]1(IV)NC1) in Figure 5B 
(bottom panel) of grant application R01 EY020539-01A1
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --HUVECs treated with hexastatin ([alpha]6(IV)NC1) in Figure 3D 
(top panel) of grant application R21 CA155796-01
    --MCECs treated with arresten ([alpha]1(IV)NC1) in Figure 5C (top 
panel) of grant application R01 EY020539-01A1
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --HUVECs treated with hexastatin ([alpha]6(IV)NC1) in Figure 3D 
(bottom panel) of grant application R21 CA155796-01,
    --MCECs treated with arresten ([alpha]1(IV)NC1) in Figure 5C 
(bottom panel) of grant application R01 EY020539-01A1
 falsifying Western blot images by reusing and falsely labeling 
one image as three different experiments:

    --The protein band FAK(P) from HUVECs treated with rh-Endo in 
Figure 4A (top panel) of PNAS 2003
    --the protein band Cox-2 from HUVECs treated with arresten 
([alpha]1(IV)NC1) in Figure 2B (top panel) of grant application R01 
CA115763-01A2, Figure 2B (top panel) of grant application R01 CA143128-
01, and Figure 2B (top panel) of grant application R01 CA143128-01A1
    --the protein band Cox-2 from MCECs treated with arresten 
([alpha]1(IV)NC1) in Figure 5C (top panel) of grant application R01 
CA143128-04 and Figure 8B (top panel) of R01 EY024967-01
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --The protein band eIF2[alpha] 51A in Figure 1A (lanes 3-5) of 
Biochem 2000
    --the protein band tumstatin ([alpha]3(IV)NC1) in Figure 2 (lanes 
2-4) of Pharm Research 2008
 falsifying Western blot images by reusing and falsely labeling 
one image as two different experiments:

    --The protein band active MMP-2 in Figure 10D (top panel, lanes 1-
4) of grant application R01 CA115763-01A2, Figure 10B of grant 
application R01 CA143128-01, Figure 10B (third panel, lanes 1-4) of 
grant application R01 CA143128-01A1, and Figure 7D (third panel, lanes 
1-4) of grant application R01 EY020539-01A1
    --the protein band arresten ([alpha]1(IV)NC1) in Figure 3C (lanes 
3-6) of Sci Reports 2014, Figure 6D (lanes 3-6) of grant application 
R01 CA143128-04, and Figure 9D (lanes 3-6) of grant application R01 
EY024967-01
 falsifying Western blot images by reusing and falsely labeling 
one image as three different experiments:


[[Page 61919]]


    --The protein band Raf from mouse lung endothelial cells (MLECs) at 
the time points 0, 5, 10, 20, and 30 minutes in Figure 5A (bottom 
panel, lanes 1-5) of JCI 2005
    --the protein band FAK(P) from MRECs at the time points 20 and 40 
minutes in Figure 7A (top panel, lanes 2 and 4) of IOVS 2009 and Figure 
5A (top panel, lanes 2 and 4) of grant application R01 EY020539-01
    --the protein band FAK from MRECs at the time points 0, 20, 20, 40, 
and 40 minutes in Figure 7A (bottom panel, lanes 1-5) of IOVS 2009 and 
Figure 5A (bottom panel, lanes 1-5) of grant application R01 EY020539-
01
 falsifying images of corneas by reusing and falsely labeling 
one image as two different experiments:

    --CNV cornea treated with arresten ([alpha]1(IV)NC1) in Figure 13 
(right panel) of grant application R01 EY020539-01
    --CNV cornea treated with tumstatin ([alpha]3(IV)NC1) in Figure 3A 
(right panel) of JCEO Sub 2011
 falsifying images of corneal sections by reusing and falsely 
labeling one image as two different experiments:

    --CNV cornea treated with arresten ([alpha]1(IV)NC1) in Figure 14 
(right panel) of grant application R01 EY020539-01
    --CNV cornea treated with tumstatin ([alpha]3(IV)NC1) in Figure 4 
(right panel) of JCEO Sub 2011
 falsifying endothelial cell migration assays by reusing and 
falsely labeling one image as two different experiments:

    --MRECs treated with vascular endothelial growth factor (VEGF) and 
arresten ([alpha]1(IV)NC1) in Figure 2A (top right panel) of IOVS 2009 
and Figure 2 (top right panel) of grant application R01 EY020539-01
    --HUVECs treated with only VEGF in Figure 1C (middle panel) of 
grant application R21 CA155796-01 and Figure 2C (second panel) of grant 
application R01 CA166195-01
 falsifying endothelial cell migration assays by reusing and 
falsely labeling one image as two different experiments:

    --MRECs treated with VEGF in Figure 2A (top middle panel) of IOVS 
2009 and Figure 2 (top middle panel) of grant application R01 EY020539-
01
    --MRECs treated with basic fibroblast growth factor (bFGF) in 
Figure 3A (second panel) of CER 2010
 falsifying endothelial cell migration assays by reusing and 
falsely labeling one image as two different experiments:

    --MRECs treated with bFGF and arresten ([alpha]1NC1) in Figure 3A 
(fourth panel) of CER 2010
    --MRECs treated with VEGF and arresten ([alpha]1NC1) in Figure 2A 
(bottom middle panel) of IOVS 2009 and Figure 2 (bottom middle panel) 
of grant application R01 EY020539-01
 falsifying endothelial cell migration assays by reusing and 
falsely labeling one image as three different experiments:

    --MRECs treated with bFGF and 10 [micro]g/ml arresten ([alpha]1NC1) 
in Figure 3A (fifth panel) of CER 2010
    --HUVECs treated with VEGF and 0.5 [micro]M hexastatin 
([alpha]6NC1) in Figure 1C (last panel) of grant application R21 
CA155796-01
    --HUVECs treated with VEGF and 0.25 [micro]M hexastatin 
([alpha]6NC1) in Figure 2C (third panel) of grant application R01 
CA166195-01
    The following administrative actions have been implemented, 
beginning on August 24, 2019:
    (1) Respondent is debarred for a period of five (5) years from 
eligibility for any contracting or subcontracting with any agency of 
the United States Government and from eligibility for, or involvement 
in, nonprocurement programs of the United States Government referred to 
as ``covered transactions'' pursuant to HHS' Implementation (2 CFR part 
376 et seq.) of Office of Management and Budget (OMB) Guidelines to 
Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 
(collectively the ``Debarment Regulations'');
    (2) Respondent is prohibited from serving in any advisory capacity 
to PHS including, but not limited to, service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant for 
a period of five (5) years; and
    (3) in accordance with 42 CFR 93 Sec. Sec.  93.407(a)(1) and 
93.411(b), HHS will send a notice of the findings and of the need for 
correction or retraction to the pertinent journals for each of the 
following:

 Biochemistry 2000;39(42):12929-12938
 Proc. Natl. Acad. Sci. U.S.A. 2003;100(8):4766-4771
 The Journal of Clinical Investigation 2005;115(10):2801-2810
 Invest. Ophthalmol. Vis. Sci. 2009;50(10):4567-4575
 Pharmaceutical Research 2008;25(12):2731-2739
 Scientific Reports 2014;4(4136):1-9
 Current Eye Res. 2010 Jan;35(1):44-55


Elisabeth A. Handley,
Interim Director, Office of Research Integrity.
[FR Doc. 2019-24689 Filed 11-13-19; 8:45 am]
 BILLING CODE 4150-31-P